학술논문
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
Document Type
Article
Author
Source
In The Lancet 21-27 October 2023 402(10411):1423-1433
Subject
Language
ISSN
0140-6736